Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting the elderly worldwide. Mitochondrial dysfunction has been proposed as a key event in the etiology of AD. We have previously modeled amyloid-beta (Aβ)-induced mitochondrial dysfunction in a transgenic Caenorhabditis elegans strain by expressing human Aβ peptide specifically in neurons (GRU102). Here, we focus on the deeper metabolic changes associated with this Aβ-induced mitochondrial dysfunction. Integrating metabolomics, transcriptomics and computational modeling, we identify alterations in Tricarboxylic Acid (TCA) cycle metabolism following even low-level Aβ expression. In particular, GRU102 showed reduced activity of a rate-limiting TCA cycle enzyme, alpha-ketoglutarate dehydrogenase. These defects were associated with elevation of protein carbonyl content specifically in mitochondria. Importantly, metabolic failure occurred before any significant increase in global protein aggregate was detectable. Treatment with an anti-diabetes drug, Metformin, reversed Aβ-induced metabolic defects, reduced protein aggregation and normalized lifespan of GRU102. Our results point to metabolic dysfunction as an early and causative event in Aβ-induced pathology and a promising target for intervention.
Dietary intervention is considered a safe preventive strategy to slow down aging. This study aimed to evaluate the protective effects of a commercially available supplement and six simpler formulations against DNA damage in 3D human keratinocytes. The ingredients used are well known and were combined into various formulations to test their potential anti-aging properties. Firstly, we determined the formulations’ safe concentration by evaluating cytotoxicity and cell viability through spectrophotometric assays. We then examined the presence of tumor p53 binding protein 1 and phosphorylated histone H2AX foci, which are markers of genotoxicity. The foci count revealed that a 24-h treatment with the supplement did not induce DNA damage, and significantly reduced DNA damage in cells exposed to neocarzinostatin for 2 h. Three of the simpler formulations showed similar results. Moreover, the antioxidant activity was tested using a recently developed whole cell-based chemiluminescent bioassay; results showed that a 24-h treatment with the supplement and three simpler formulations significantly reduced intracellular H2O2 after pro-oxidant injury, thus suggesting their possible antiaging effect. This study’s originality lies in the use of a 3D human keratinocyte cell model and a combination of natural ingredients targeting DNA damage and oxidative stress, providing a robust evaluation of their anti-aging potential.
Aging is a multifaceted process influenced by intrinsic and extrinsic factors, with lipid alterations playing a critical role in brain aging and neurological disorders. This study introduces DoliClock, a lipid-based biological aging clock designed to predict the age of the prefrontal cortex using post-mortem lipidomic data. Significant age acceleration was observed in samples with autism, schizophrenia, and Down syndrome, with autism showing the most pronounced effects in aging-rate. An increase in entropy around age 40, suggests dysregulation of the mevalonate pathway and dolichol accumulation. Dolichol, a lipid integral to N-glycosylation and intracellular transport, emerged as a potential aging biomarker, with specific variants such as dolichol-19 and dolichol-20 showing unique age-related associations. These findings suggest that lipidomics can provide valuable insights into the molecular mechanisms of brain aging and neurological disorders. By linking dolichol levels and entropy changes to aging, this study highlights the potential of lipid-based biomarkers for understanding and predicting biological age, especially in conditions associated with premature aging.
Nutraceuticals, bioactive compounds derived from foods, are increasingly investigated as interventions to promote healthy ageing. Multi-ingredient formulations may offer additive or synergistic benefits by targeting multiple ageing pathways while using low doses of each component for improved safety. However, their efficacy in mammals remains poorly understood. Here, we compared the effects of a continuous multi-ingredient nutraceutical intervention with two short-courses of senolytic regimen in naturally aged male C57Bl/6J mice. Importantly, these mice were overweight following a switch to soaked food at 20 months, a protocol that increased caloric intake and likely induced metabolic stress. This context frames the study as a model of ‘rescue’ from premature ageing rather than extension of maximum lifespan. Mice were assigned to either control, nutraceutical (12 pro-longevity natural compounds), or senolytic (Navitoclax plus BAM15) groups at 20 months of age. Lifespan and healthspan indicators were assessed longitudinally. Both interventions improved survival compared to controls (median lifespan +18–21%) and mitigated frailty progression, but with distinct patterns: nutraceutical benefits accumulated gradually, whereas senolytic effects were transient. Cognitive performance was preserved in nutraceutical-treated mice and improved shortly after senolytic treatment. In vitro, the nutraceutical lacked senolytic activity but exhibited senostatic effects, reducing nuclear size, ROS release, and IL-6 secretion in senescent fibroblasts. These findings suggest that multi-ingredient nutraceuticals can restore healthspan compromised by metabolic stress and deliver benefits comparable to senolytics when administered continuously, potentially through senostatic mechanisms. Combining senolytics to reduce senescent burden with long-term nutraceutical treatment may offer a safe, accessible strategy to optimise healthspan, particularly in the context of modern human ageing, which often occurs under conditions of caloric excess and metabolic syndrome.
Currently, no generalizable tools exist for predicting the impact of interventions on aging using gene expression changes. Here, we build a model for predicting potential geroprotectors by deconstructing the aging transcriptome into coexpression modules and identifying those modulated by life span–extending interventions in Caenorhabditis elegans ( C. elegans ). Many of these modules exhibited adaptive changes during aging that are linked to longevity. Using these longevity-associated modules, we predicted and validated 10 compounds (7 previously unreported) that significantly extended life span in C. elegans . RNA sequencing analysis of two top candidates also showed targeted modulation of our longevity-associated modules. We identified conservation of several modules in mice that were also correlated with frailty. Together, our findings demonstrate that beneficial transcriptomic adaptations occur during aging and that targeting longevity-associated modules offers a framework for geroprotector discovery.
Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting the elderly worldwide. Mitochondrial dysfunction has been proposed as a key event in the etiology of AD. We have previously modeled amyloid-beta (Aβ)-induced mitochondrial dysfunction in a transgenic Caenorhabditis elegans strain by expressing human Aβ peptide specifically in neurons (GRU102). Here, we focus on a deeper analysis of these metabolic changes associated with Aβ-induced mitochondrial dysfunction. Integrating metabolomics, transcriptomics, biochemical studies and computational modeling, we identify alterations in Tricarboxylic Acid (TCA) cycle metabolism following even low-level Aβ expression. In particular, GRU102 show reduced activity of a rate-limiting TCA cycle enzyme, alpha-ketoglutarate dehydrogenase. These defects are associated with elevation of protein carbonyl content specifically in mitochondria. Importantly, metabolic failure occurs before any significant increase in global protein aggregate is detectable. Treatment with an antidiabetes drug, Metformin, reverses Aβ-induced metabolic defects, reduces protein aggregation and normalizes the lifespan of GRU102. Our results point to metabolic dysfunction as an early and causative event in AD pathology and a promising target for intervention.